ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.60
0.71%
US Tech 100
19,636.04
0.55%
S&P 500
5,770.20
0.55%
US Dollar vs CAD
1.43715
0.00%
Bitcoin
86,039.06
-0.13%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Verona Pharma Plc (VRNA) Share Price

Verona Pharma Plc

Verona Pharma Plc (VRNA)

NASDAQ
64.65
-1.02
(-1.55%)
Closed March 08 3:00PM
Delayed by 15 minutes
64.95
0.30
(0.46%)
After Hours: 6:03PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
64.95
Bid
64.71
Ask
69.00
Volume
1,296,792
63.03 Day's Range 67.5082
0.00 52 Week Range 0.00
Market Cap
5.519B
Previous Close
65.67
Open
66.20
Last Trade
404
@
64.95
(formt)
Last Trade Time
Financial Volume
US$ 84,433,177
VWAP
65.1093
Average Volume (3m)
-
Shares Outstanding
84,978,881
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-54.37M

About Verona Pharma Plc

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which ... Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.veronapharma.com
Headquarters
London, Gbr
Founded
-
Verona Pharma Plc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VRNA. The last closing price for Verona Pharma was US$65.67. Over the last year, Verona Pharma shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Verona Pharma currently has 84,978,881 shares outstanding. The market capitalization of Verona Pharma is US$5.58 billion.

Ask ADVFN Intelligence (AI)

Verona Pharma (VRNA) Options Flow Summary

VRNA Options Flow

Overall Flow

Bullish

Net Premium

585k

Calls / Puts

100.00%

Buys / Sells

37.50%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

VRNA Latest News

More News

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
February 27 2025
VRNA (-1.55%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
February 27 2025
VRNA (-1.55%)

Form 8-K - Current report
Edgar (US Regulatory)
February 27 2025
VRNA (-1.55%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 04 2025
VRNA (-1.55%)

Form 8-K - Current report
Edgar (US Regulatory)
January 07 2025
VRNA (-1.55%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
November 26 2024
VRNA (-1.55%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

VRNA - Frequently Asked Questions (FAQ)

What is the current Verona Pharma share price?
The current share price of Verona Pharma is US$ 64.95
How many Verona Pharma shares are in issue?
Verona Pharma has 84,978,881 shares in issue
What is the market cap of Verona Pharma?
The market capitalisation of Verona Pharma is USD 5.58B
What is the 1 year trading range for Verona Pharma share price?
Verona Pharma has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the reporting currency for Verona Pharma?
Verona Pharma reports financial results in USD
What is the latest annual profit for Verona Pharma?
The latest annual profit of Verona Pharma is USD -54.37M
What is the registered address of Verona Pharma?
The registered address for Verona Pharma is ONE CENTRAL SQUARE, CARDIFF, LONDON, CF10 1FS
What is the Verona Pharma website address?
The website address for Verona Pharma is www.veronapharma.com
Which industry sector does Verona Pharma operate in?
Verona Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ABLVAble View Global Inc
US$ 1.73
(137.18%)
5.14M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
DWTXDogwood Therapeutics Inc
US$ 6.63
(49.66%)
25.92M
KZIAKazia Therapeutics Ltd
US$ 1.1899
(40.80%)
4.5M
ALBTAvalon GloboCare Corporation
US$ 6.96
(-36.15%)
570.43k
SCNXScienture Holdings Inc
US$ 1.55
(-35.68%)
1.54M
ACXPAcurx Pharmaceuticals Inc
US$ 0.4572
(-29.88%)
1.13M
RETOReTo Eco Solutions Inc
US$ 5.42
(-27.73%)
108k
OCTOEightco Holdings Inc
US$ 1.08
(-27.03%)
332.1k
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
618.03M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
476.73M
NVDANVIDIA Corporation
US$ 112.69
(1.92%)
333.91M
ICONIcon Energy Corporation
US$ 0.169898
(17.17%)
140.23M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.675
(-0.70%)
140.05M

VRNA Discussion

View Posts
powerwalker powerwalker 2 days ago
Verona Pharma plc (VRNA): A Bull Case Theory

https://finance.yahoo.com/news/verona-pharma-plc-vrna-bull-132023995.html
👍️0
powerwalker powerwalker 2 days ago
Agree ... I think it will be a crooked number(s) above $10B.
👍️ 1
Hoskuld Hoskuld 2 days ago
I think it will exceed $10b by a large margin.
👍️0
MegaPirate61 MegaPirate61 4 days ago
Mentioned very active in seeking a partner for eu. Did not object to 3, 5, or even 10b per yr peak market
👍️ 1
Hoskuld Hoskuld 4 days ago
PW, I did not listen because they just gave their conference call last week. I missed downloading the live transcript, too, which I wish I would have grabbed!
👍️0
powerwalker powerwalker 5 days ago
What did VRNA execs state at the Cowen meeting this morning?
👍️0
Monksdream Monksdream 7 days ago
VRNA six months chart
👍️ 1
Hoskuld Hoskuld 7 days ago
If at $625m run rate by end of Q1 (current pace suggests this) and uptake continue at least at this pace, then Q2 would end with roughly the 64,000 patients it takes to get to a $1b run rate, and Q3 would end with $1.4b run rate, and Q4 would end with a $1.8b run rate. I think progress will be better the more I look at this, so let's say $2b run rate. That would make it possible - I mean just possible - that 2025 revenue could reach that $1b level. That would be ahead of schedule and point to the $5b-$10b revenue area that I think we are headed for (US market only.)
👋 1 👍️ 2
Hoskuld Hoskuld 1 week ago
That is over $600m in annual revenue.
👍️ 2
Hoskuld Hoskuld 1 week ago
Seems possible if the macro environment holds together and current uptake continues.
👍️ 1
powerwalker powerwalker 1 week ago
$100 by the end of June?
👍️ 1
powerwalker powerwalker 1 week ago
With 40,000 patients, that is almost a half of a Billion in revenue annually.

Go VERONA!
👍️ 1
Hoskuld Hoskuld 1 week ago
And yet the revenue number given to justify that is so much lower than what will actually be realized.
👍️ 1
powerwalker powerwalker 1 week ago
Wells Fargo analyst Tiago Fauth maintains Verona Pharma (VRNA) with a Overweight and raises the price target from $74 to $93.

Nice to see such an increase in the target.
👍️ 1
Hoskuld Hoskuld 1 week ago
They were asked but didn't give specifics.
👍️ 1
powerwalker powerwalker 1 week ago
So, Hoskuld, what about EU and UK? Are there any plans to file for approval?
👍️0
Hoskuld Hoskuld 1 week ago
40,000 by end of March seems very do-able. I think share price will more than double by year end.
👍️ 2
powerwalker powerwalker 1 week ago
Almost a double since y/e ... may it continue at that pace!
👍️ 1
Hoskuld Hoskuld 1 week ago
30,000 as of yesterday.
👍️ 1 🚀 1
Roger1 Roger1 1 week ago
Tuned in late. Did they give an updated patient count for Jan or feb? TIA
👍️0
Hoskuld Hoskuld 1 week ago
This is a spectacular launch to date.
👍️ 1 🚀 1
powerwalker powerwalker 1 week ago
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

https://www.veronapharma.com/news/verona-pharma-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporate-update/
👍️0
powerwalker powerwalker 1 week ago
Roger, how are you feeling?
👍️0
Roger1 Roger1 1 week ago
Time of cc signals good news, imo
👍️ 1 🙏 1 🤞 1
powerwalker powerwalker 2 weeks ago
Given the quick move to $65.70 and subsequent halving of the gain, it seems MM's still seeking weak hands ... especially with tomorrow's CC before the market opens looming!
👍️0
Hoskuld Hoskuld 2 weeks ago
Yes the high end is reasonable but the low end seems too low to credit. Zero new patients results in...16,000 patients = $250m per year, divided by 4 gives $62m for current quarter. If they add the bare minimum new patients during CQ (1,000 per week) then that would be average of 22,500 partients = $87m for CQ.
👍️ 1
MegaPirate61 MegaPirate61 2 weeks ago
Estimated outlook for cq are between 65 and 90 million
👍️0
Hoskuld Hoskuld 2 weeks ago
Roger, the average for Q4 was just over 1,000 patients per week with momentum building through the end of the year despite holidays. My estimate is, IMO, extremely conservative: no additional growth in new patients per week. This seems unlikely though so I expect those estimates of mine are low.
👍️ 1
Roger1 Roger1 2 weeks ago
That would be awesome
👍️0
Hoskuld Hoskuld 2 weeks ago
They had 16,000 patients on ohtuveyre as of 31DEC and I bet they announce that they have 25,000 patients as of 14FEB or 27,000 as of 24FEB.
👍️ 1
Roger1 Roger1 2 weeks ago
Thanks. Looking forward to seeing quarterlies next week. Anyone speculate on uptake for January?
👍️0
Hoskuld Hoskuld 2 weeks ago
Roger, buyout would be based on strength of market acceptance and uptake. BP should have already purchased for $100 per share, now the price will be $120 and will grow to $150-$200 as the next year plays out. A buyout could happen at any time - should happen at any time - but who knows?
👍️ 1
Roger1 Roger1 2 weeks ago
How high does this go before getting taken out?
👍️0
powerwalker powerwalker 2 weeks ago
I am interested in Verona's comments on filing an MAA with the EMA. Hopefully, they have or will be doing so soon.
👍️0
powerwalker powerwalker 3 weeks ago
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

https://www.veronapharma.com/news/verona-pharma-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-corporate-update/
👍️0
powerwalker powerwalker 3 weeks ago
Does anyone have any thoughts as to today's gain?
👍️0
Roger1 Roger1 1 month ago
I can tell you that I've been off steroids for 3 weeks.
👍️ 4 💥 1
powerwalker powerwalker 1 month ago
Hello, Roger:

Is there any update on your condition which you would like to share?

Thank you,
powerwalker
👍️0
Monksdream Monksdream 1 month ago
VRNA 1 yr
👍️ 1
MegaPirate61 MegaPirate61 1 month ago
For 2025, Stan Druckenmiller
made his long pick in the Robin Hood contest in Verona Pharma (VRNA). Verona's inhaled treatment for adults with chronic obstructive pulmonary disease (COPD) won FDA approval last June. On Jan. 8, it said fourth-quarter sales totaled $36 million in the multi-billion dollar blockbuster indication.
👍️ 3
powerwalker powerwalker 1 month ago
Is Verona Pharma (VRNA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

https://finance.yahoo.com/news/verona-pharma-vrna-among-billionaire-201156030.html
👍️ 2 😃 1
MegaPirate61 MegaPirate61 2 months ago
According to a msg board post the cfo said that their quarterly expenses were 50 million and sales were now break even and will soon be exceeding that.
👍️ 2
powerwalker powerwalker 2 months ago
While it might not be making a presentation, Verona execs are at the JPM Healthcare Conference, partaking in meetings with future impact.
👍️0
MegaPirate61 MegaPirate61 2 months ago
Posted a typo before the released shares that were already on the shelf total was 2.5 million shares not 12.5 mil
👍️0
Roger1 Roger1 2 months ago
Yes
👍️ 3
Hoskuld Hoskuld 2 months ago
Do you ascribe this improvement to ohtuvayre Roger? Congratulations!
👍️ 1
Roger1 Roger1 2 months ago
Good news. I've been able to cut my Prednisone in half and hopefully eliminate it soon. Have found I can stretch my nebulizer treatments to Q6-7 from Q4. Will be interesting to see how much more improvement I can get b4 allergy season in Mar/April.
👍️ 3
powerwalker powerwalker 2 months ago
Roger, what is going on with you and your ohtuvayre experience?

We would like to hear about it.
👍️ 2
MegaPirate61 MegaPirate61 2 months ago
Well they went and announced unofficial earnings on their own today. Also says they sold 12.5 million shares at an avg of 39.50 of so through Jeffries. Must have something else to announce at jpm?
👍️ 1
powerwalker powerwalker 2 months ago
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

https://finance.yahoo.com/news/verona-pharma-reports-strong-ohtuvayre-110000636.html

Sounds positive and noted the "J-code" that MegaPirate had emphasized. 👍️❤️
👍️ 1

Your Recent History

NASDAQ
VRNA
Verona Pharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads